Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase 2 2Phase 1 2Phase 1/2 1

Status

Withdrawn 1Completed 1

Sponsor Class

OTHER 16NIH 3NETWORK 3INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 1Breast 1

Conditions

Leukemia, Myeloid, Acute 1Breast Neoplasms 1

Interventions

pembrolizumab 301Paclitaxel 206Carboplatin 199Gemcitabine 173Cisplatin 138Docetaxel 137Cyclophosphamide 135Nivolumab 129Bevacizumab 118Injections 111fludarabine 95atezolizumab 91Pemetrexed 90Dexamethasone 90Cetuximab 90Fluorouracil 84Irinotecan 77Rituximab 72Capecitabine 72venetoclax 70Azacitidine 70130-nm albumin-bound paclitaxel 67Leucovorin 65Fulvestrant 58Oxaliplatin 57durvalumab 56Trastuzumab 56Lenalidomide 55Ipilimumab 55Midazolam 54

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × INDUSTRY × Neoadjuvant Therapy × Clear all
NCT02326584 2018-05-09

A Safety Study of SGN-CD33A in Combination With Standard-of-care in Patients With AML

Seagen Inc.

Phase 1 Completed
116 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT00635245 2015-03-11

CP-751871 In Treating Women With Early-Stage Breast Cancer That Can Be Removed By Surgery

Pfizer

Phase 1 Withdrawn
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡